Published in:
Open Access
01-12-2020 | Infliximab | Research Letter
Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure—a cautionary case series
Authors:
Andreas Stallmach, Andreas Kortgen, Falk Gonnert, Sina M. Coldewey, Philipp Reuken, Michael Bauer
Published in:
Critical Care
|
Issue 1/2020
Login to get access
Excerpt
The severe acute respiratory coronavirus 2 (SARS-CoV-2) pandemic has prompted search for therapeutics tackling both the pathogen and the overwhelming host response, on an unprecedented scale. In a minority of patients, the disease may cause frequently lethal complications from acute respiratory distress syndrome to multisystem organ failure presumably driven by a cytokine storm [
1]. Therefore, anti-cytokine therapies may be helpful to prevent tissue injury. However, these anti-inflammatory drugs constitute double-edged swords; while they can prevent organ damage, they increase the risk of concomitant (super)infection. …